title: Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab.
authors.affiliation: Department of Haemato-Oncology, John Vane Cancer Centre, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, UK.
authors.forename: C L
authors.initials: CL
authors.lastname: Freeman
authors.affiliation: Department of Biostatistics, Roche Products Limited, Welwyn Garden City, UK.
authors.forename: M
authors.initials: M
authors.lastname: Dixon
authors.affiliation: Department of Statistical Programming and Analysis, Roche Products Limited, Welwyn Garden City, UK.
authors.forename: R
authors.initials: R
authors.lastname: Houghton
authors.affiliation: German CLL Study Group, Center of Integrated Oncology Cologne-Bonn, Department of Internal Medicine, University Hospital Cologne, Cologne, Germany.
authors.forename: K-A
authors.initials: KA
authors.lastname: Kreuzer
authors.affiliation: Pharma Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
authors.forename: G
authors.initials: G
authors.lastname: Fingerle-Rowson
authors.affiliation: German CLL Study Group, Center of Integrated Oncology Cologne-Bonn, Department of Internal Medicine, University Hospital Cologne, Cologne, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Herling
authors.affiliation: Pharma Development Clinical Science, Roche Products Limited, Welwyn Garden City, UK.
authors.forename: K
authors.initials: K
authors.lastname: Humphrey
authors.affiliation: University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Böttcher
authors.affiliation: Roche Pharmaceutical Research and Early Development (pRED), Pharmaceutical Sciences (PS), Roche Innovation Centre Basel, Basel, Switzerland.
authors.forename: C S
authors.initials: CS
authors.lastname: de Costa
authors.affiliation: Roche Pharmaceutical Research and Early Development (pRED), Pharmaceutical Sciences (PS), Roche Innovation Centre Basel, Basel, Switzerland.
authors.forename: V
authors.initials: V
authors.lastname: Iglesias
authors.affiliation: Department of Internal Medicine III, Ulm University, Ulm, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Stilgenbauer
authors.affiliation: Department of Haemato-Oncology, John Vane Cancer Centre, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, UK.
authors.forename: J
authors.initials: J
authors.lastname: Gribben
authors.affiliation: German CLL Study Group, Center of Integrated Oncology Cologne-Bonn, Department of Internal Medicine, University Hospital Cologne, Cologne, Germany.|Department I of Internal Medicine Centre of Integrated Oncology Köln Bonn and Cluster of Excellence on Cellular Stress Responses in Aging (CECAD) University of Cologne, Cologne, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Hallek
authors.affiliation: German CLL Study Group, Center of Integrated Oncology Cologne-Bonn, Department of Internal Medicine, University Hospital Cologne, Cologne, Germany.|Department I of Internal Medicine Centre of Integrated Oncology Köln Bonn and Cluster of Excellence on Cellular Stress Responses in Aging (CECAD) University of Cologne, Cologne, Germany.
authors.forename: V
authors.initials: V
authors.lastname: Goede
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D018951:Antigens, CD20 / Q000096:biosynthesis*; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000378:metabolism; D016017:Odds Ratio; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012307:Risk Factors; D000069283:Rituximab / Q000009:adverse effects
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20; D000074322:Antineoplastic Agents, Immunological; D000069283:Rituximab; C543332:obinutuzumab